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Abstract
Sphingolipids, lipids with a common sphingoid base (also termed long chain base) backbone, play essential cellular
structural and signaling functions. Alterations of sphingolipid levels have been implicated in many diseases, including
neurodegenerative disorders. However, it remains largely unclear whether sphingolipid changes in these diseases are
pathological events or homeostatic responses. Furthermore, how changes in sphingolipid homeostasis shape the
progression of aging and neurodegeneration remains to be clarified. We identified two mouse strains, flincher (fln) and
toppler (to), with spontaneous recessive mutations that cause cerebellar ataxia and Purkinje cell degeneration. Positional
cloning demonstrated that these mutations reside in the Lass1 gene. Lass1 encodes (dihydro)ceramide synthase 1 (CerS1),
which is highly expressed in neurons. Both fln and to mutations caused complete loss of CerS1 catalytic activity, which
resulted in a reduction in sphingolipid biosynthesis in the brain and dramatic changes in steady-state levels of sphingolipids
and sphingoid bases. In addition to Purkinje cell death, deficiency of CerS1 function also induced accumulation of lipofuscin
with ubiquitylated proteins in many brain regions. Our results demonstrate clearly that ceramide biosynthesis deficiency can
cause neurodegeneration and suggest a novel mechanism of lipofuscin formation, a common phenomenon that occurs
during normal aging and in some neurodegenerative diseases.
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Introduction
A hallmark of aging and many neurodegenerative disorders is
the neuronal accumulation of storage materials. These deposits
include lipofuscin that contain undigested membranes and
defective proteins [1], and/or membrane-free aggregates of
misfolded proteins [2]. While the pathological roles of these
accrued substances are unclear and may vary between diseases,
their sequestration may protect neurons from those components
that are otherwise highly toxic in soluble forms [3]. However,
evidence also suggests that insoluble storage materials are
inherently toxic, and in some circumstances these materials may
lead to the inhibition of proteasomal and lysosomal functions,
which in turn accelerates their further deposition [4].
In addition to the accumulation of storage materials and
impaired protein degradation capacity, changes in cellular
homeostasis, including alterations in both simple and complex
sphingolipid composition, also occur in the brains of patients with
neurodegenerative diseases and in the aging brain [5,6]. These
highly diverse lipids play important structural and signaling
functions in the cell, and mediate cell-cell interaction [7,8].
Increases in levels of specific species of ceramide, the simplest
sphingolipid, have been found in the brains of Alzheimer’s disease
(AD) patients and a mouse model of AD, and correlate with
disease severity [6,9,10]. Similarly, long-chain and very long-chain
ceramide species are increased in the brains of HIV-associated
dementia patients [11]. Changes in several sphingolipid classes
have been observed in the brains of patients with progressive
epilepsy with mental retardation (EPMR), a form of neuronal
ceroid lipofuscinosis (CLN8) [12]. Furthermore, sphingolipids
have been implicated in Parkinson’s disease (PD) and Huntington’s
disease (HD) [13]. For example, glucocerebrosidase mutations
have been suggested to be risk factors for PD and other Lewy body
disorders [14]. Fibroblasts of HD patients and the brain of HD
animal models exhibit reduced GM1 ganglioside levels [15].
Lastly, changes in sphingolipids have also been associated with
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involved in sphingolipid degradation. Storage of sphingolipids in
these diseases results in global impairment of lysosomal function
[16]. This in turn blocks lysosomal degradation of defective
proteins and organelles.
While we are beginning to understand the molecular pathology
of sphingolipid-related and other lysosomal storage diseases, the
roles of sphingolipid metabolism in the progression of aging and
neurodegeneration are still not clear. It was reported that
disruption of the Lass2 gene that encodes ceramide synthase 2
(CerS2), caused myelin degeneration, consistent with the restricted
expression of this gene within the brain to oligodendrocytes, and
secondary loss of cerebellar granule cells [17]. This finding
demonstrates that reduction of sphingolipid levels is indeed
pathogenic in the brain, at least in oligodendrocytes. Here we
report that deficiency of Lass 1 that encodes CerS1, a ceramide
synthase that is predominantly expressed in neurons [18,19],
causes progressive Purkinje cell loss in mice. We also show that
CerS1 plays a key role in ceramide biosynthesis in the brain, and
loss of this protein dramatically impacts many aspects of
sphingolipid homeostasis. Lastly, we find that loss of CerS1 leads
to accumulation of lipofuscin that are associated with ubiquitylated
proteins in many regions of the brain, suggesting that ceramide
biosynthesis is critical for protein and organelle homeostasis. These
data demonstrate that lipid biosynthesis defects in neurons can
directly cause cell death. Furthermore, our results establish a
causal link between lipid biosynthesis deficiencies and lipofuscin
accumulation, and may provide a common mechanism for
deposition of lipofuscin in aging and neurodegenerative diseases.
Results
Cerebellar Purkinje cell defects in the flincher mutant
brain
The flincher (fln) mutation arose spontaneously in a colony of
NOD.CB17-Prkdc
scid/SzJ mice at The Jackson Laboratory. Mice
homozygous for the fln mutation were hyperactive and generally
smaller in body size beginning at postnatal day seven. By three
weeks of age, the size difference between mutant mice and their
littermates was very obvious. Although mutant mice continued to
gain weight until reaching maturity, adult mutant mice progres-
sively lost weight, like other ataxic mice. However, the lifespan of
mutant mice was comparable to that of their wild type or
heterozygous littermates despite their weight loss and severe
ataxia.
Flincher mutant mice displayed cerebellar ataxia beginning at
three weeks, which was concomitant with degeneration of
cerebellar Purkinje cells (Video S1, Figure 1A and data not
shown). Neuron loss was progressive, and many Purkinje cells had
degenerated in mutant mice by four months of age (Figure 1B–
1D). Although the soma of Purkinje cells appeared normal in the
mutant mice prior to three weeks of age, at postnatal day twelve
(P12), Purkinje cell dendritic arbors were shorter than those in the
wild type cerebellum (Figure 1E–1F). This reduction of dendritic
arbor size was more pronounced by P17 (Figure 1G–1H). In
addition, the reduced density of calbindin immunostaining in the
molecular layer at P17 suggested that the complexity of higher
order branches of mutant Purkinje cell dendritic arbors may also
be reduced compared to that of wild type dendrites.
The flincher mutation disrupts the Lass1 gene
To identify the molecular defect in fln mutant mice, we crossed
fln/fln and BALB/cByJ mice, and performed genome scans on F2
mice using sequence tagged site (STS) markers. This analysis
localized the fln mutation to Chromosome 8. Fine mapping using
these F2 mice and additional F2 mice from a fln6CAST/EiJ cross
narrowed the fln mutation to a 0.04 cM (0.8 Mb) region between
two single nucleotide polymorphisms (SNPs), D8SlacAT1 and
rs6348000 (two recombinants/1984 F2 mice), containing 34
known protein-encoding genes (Figure 2A, Figure S1 and Figure
S2A). To further define the mutant locus, transgenic mice carrying
bacteria artificial chromosomes (BACs) containing genes from the
fln critical interval were generated and crossed with mutant mice
(Figure S2A). Among the three BACs used to make transgenic
mice, only BAC RP23-349E13 was able to complement the fln
mutant phenotype (Figure S2B–S2C). BAC RP23-349E13 con-
tains nine known genes (Figure 2B) and the expression of one of
these genes, Lass1, was greatly reduced in fln/fln brains (Figure 2C,
left panels). Sequencing of Lass1 RT-PCR products revealed a
single nucleotide deletion in exon 5, which results in a frameshift
mutation that likely leads to nonsense-mediated decay of the Lass1
transcript in fln mutant brains (Figure 2D, left panels).
Lass1 is transcribed as a part of an unusual bicistronic transcript
that also encodes growth differentiation factor-1 (GDF1), a member
of the TGF-ß family [20]. Thus, as expected, Gdf1 expression is also
reduced inflnmutantbrains(Figure 2C,left panels).To determine if
the fln phenotype is a result of loss of Lass1 or of decreased Gdf1
function, we performed cDNA transgenic complementation
experiments. Transgenic mice expressing the Lass1 cDNA under
the control of the neuron-specific enolase (NSE) promoter were
generated and mated with fln mutant mice to generate fln/fln mice
carrying the Lass1 transgene. These mice did not develop ataxia nor
did they have Purkinje cell degeneration, demonstrating that
expression of Lass1 in neurons is sufficient to rescue fln-mediated
Purkinje cell degeneration (Figure 2E–2F and data not shown).
Therefore, loss of Lass1, not Gdf1, function underlies the
neuropathology observed in fln mutant mice.
Toppler (to) is a point mutation in the Lass1 gene
Toppler (to), a spontaneous recessive mutation causing Purkinje
cell degeneration beginning around three weeks after birth, was
also mapped to the middle of Chromosome 8 [21]. Postnatal
Purkinje cells in to mutant cerebella also display higher order
Author Summary
Lipids play many essential cellular roles as structural
components of biological membranes or signaling mole-
cules. Alterations of lipids have been observed in the
brains of patients with neurodegenerative diseases.
However, whether these changes can cause neurodegen-
eration or otherwise influence the pathology of these
diseases is unclear. We identified mouse mutations in a
gene encoding a neuronally expressed enzyme that
generates ceramide, the basic structural component of
many lipids known as sphingolipids. These mutations
result in progressive ataxia and loss of cerebellar Purkinje
cells. In addition, many neurons in these mutant mice
harbor lipofuscin, a storage material containing both
membranes and proteins, that is present in aging brains
and in brains of patients with neurodegenerative disor-
ders, suggesting that both membrane and protein
homeostasis are impaired in mutant neurons. This study
directly demonstrates that disruption of sphingolipid
biosynthesis can lead to selective neuron death and the
abnormal accumulation of lipofuscin, and it underscores
the need for further study of the roles of lipids in
neurodegenerative disorders.
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phenotypic similarity, we proposed that to and fln mutations were
allelic and performed complementation tests. Fln/+; to/+ com-
pound heterozygous mice exhibited progressive ataxia beginning
at three weeks of age (data not shown). These mice also had
Purkinje cell degeneration that was indistinguishable from that was
observed in mice homozygous for either the to or the fln mutation
(data not shown), indicating that the to mutation also likely disrupts
the Lass1 gene. This inference was confirmed by the rescue of the
to mutant phenotype by the Lass1 cDNA transgene (Figure S3A–
S3B). Although the RNA expression level of the bicistronic Lass1-
Gdf1 transcript was not affected by the to mutation (Figure 2C,
right panels), sequencing of Lass1 RT-PCR products from toppler
mutants revealed a missense point mutation in exon 5 resulting in
the change of residue Ala266 to Asp (Figure 2D, right panel, and
Figure S4B). These results confirmed that the Lass1 gene underlies
the pathological changes in both fln and to mutant mice.
The fln and to mutations disrupt ceramide synthase 1
enzymatic activity
The Lass1 gene encodes the (dihydro)ceramide synthase CerS1,
one of the six (dihydro)ceramide synthases (CerS1–CerS6) in
mammals, encoded by Lass1 to Lass6, respectively [22]. In the de
novo pathway of ceramide biosynthesis, these enzymes catalyze the
condensation of fatty acyl-CoA and dihydrosphingosine (dhS, also
known as sphinganine) to produce dihydroceramide (Figure 3A).
Dihydroceramide, in turn, is desaturated on the dhS backbone by
dihydroceramide desaturase to form ceramide, which is the basic
building block for complex sphingolipids. In vitro overexpression
studies demonstrated that each of the six mammalian ceramide
synthases has different fatty acyl-CoA substrate specificity and
saturated C18:0 fatty acyl-CoA is the preferred substrate for CerS1
[23–25]. These studies also demonstrated that CerS1 could also
use C16:0 and C20:0 fatty acid-CoA, albeit inefficiently, but not the
unsaturated C18:1 fatty acyl-CoA that contains a D9 cis double
bond [25].
Similar in vitro assays suggested that C18:0 fatty acyl-CoA can
also serve as a substrate for CerS5, a CerS with broader
substrate specificity [25]. However, CerS5 is expressed at a
lower level than that of CerS1 in the mouse brain [25].
Together these data suggested that the reduction of CerS1
function in the mouse brain would significantly decrease the
activities of ceramide synthases that utilize C18 fatty acyl-CoA.
To test this hypothesis, we analyzed ceramide synthase activity
Figure 1. Progressive cerebellar Purkinje cell degeneration and abnormalities of Purkinje dendritic arbors in fln/fln mice. (A–D)
Calbindin D-28 immunostained sagittal sections of cerebella from three-week-old (B), four-week-old (B) and four-month-old fln/fln (C), and four-
month-old wild type (+/+, D) mice. Sections were counterstained with hematoxylin. Cerebellar lobules are indicated by Roman numerals. (E–H)
Purkinje cells immunostained with calbindin D-28 from wild type (E, G) and fln/fln (F, H) mice at P12 (E, F) and P17 (G, H). Scale bars: 1 mm (A–D);
50 mm (E–H).
doi:10.1371/journal.pgen.1002063.g001
CerS1 Deficiency Causes Neurodegeneration
PLoS Genetics | www.plosgenetics.org 3 May 2011 | Volume 7 | Issue 5 | e1002063with three fatty acyl-CoA substrates, including C18:0 fatty acyl-
CoA, in microsomes prepared from wild type and mutant brain
homogenates. The activity for C18 fatty acyl-CoA was reduced
drastically in fln/fln brain microsomes, indicating that CerS1 is
the major CerS in the brain using C18 fatty acyl-CoA
(Figure 3B). No difference in ceramide synthase activity for
C16 or C24 fatty acyl-CoA was observed between wild type and
fln mutant brain microsomes, confirming the high specificity of
CerS1 for C18 fatty acyl-CoA, and suggesting that the activities
of other ceramide synthase isoenzymes present in the brain were
not affected by the severely reduced CerS1 activity (Figure 3C
and data not shown).
CerS1 is a multiple transmembrane domain protein and shares
a conserved TRAM-LAG1-CLN8 (TLC) domain with other
CerSs. The fln and to mutations reside between the last two
predicted transmembrane domains. This region is within the TLC
domain but outside of the LAG1 motif that was previously shown
to be indispensible for the catalytic activity (Figure S4A) [26]. Mice
homozygous for either mutation have very similar phenotypes,
suggesting that the Ala266Asp to mutation may also result in a
dramatic loss of CerS1 function. To test this possibility, plasmids
encoding wild type and mutant CerS1 proteins, each with an N-
terminal FLAG epitope, were transfected into COS7 cells.
Microsomes prepared from transfected cells were assayed for
Figure 2. Genome mapping and identification of the flincher and toppler mutations. (A) The critical mapping interval of the fln mutation is
between D8SlacAT1 and rs6348000. (B) The genes encoded in BAC RP23-349E13 that was used to construct the fln-rescuing BAC transgenic line. (C)
Northern blot analyses of fln/fln and to/to brain mRNA hybridized with probes to Lass1 and Gdf1. Blots were re-hybridized with a Gapdh probe as a
loading control. (D) Sequence chromatograms of wild type (+/+), fln/fln and to/to Lass1 cDNA reveal a single nucleotide deletion (underlined in the
wild type chromatogram) in fln/fln mice and a missense mutation (underlined) in to/to mice. (E–F) Calbindin D-28 immunohistochemistry of cerebella
from 8-week-old fln/fln (E) and fln/fln; Tg(NSE-Lass1) (F) mice.
doi:10.1371/journal.pgen.1002063.g002
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crude enzymatic activity was normalized to the levels of FLAG-
tagged CerS1. Both fln and to mutations impart almost complete
loss of CerS1 catalytic activity, demonstrating that the carboxyl
end of the TLC domain, and residue Ala266 in particular, are
indispensible for CerS1 function (Figure 3D).
To investigate the effect of CerS1-deficiency on sphingolipid
homeostasis in the brain, total lipids were extracted from wild type
and fln mouse brains, and subjected to liquid chromatography
coupled mass spectrometry (LC-MS). The total amount of
ceramide was decreased by approximately 50%, confirming that
CerS1 is a major CerS in the brain (Figure 4A). In line with the
previous report on the preference of CerS1 for C18:0 fatty acyl-
CoA, C18:0 ceramide was reduced approximately two fold in the
mutant samples (Figure 4B). Although previous in vitro data
demonstrated that unsaturated C18:1 fatty acyl-CoA was not
utilized by CerS1 [25], the level of C18:1 ceramide was decreased
more than five fold in the fln mutant brain suggesting that either
Figure 3. The fln and to mutations impair ceramide synthase activity of CerS1. (A) Schematic diagram of mammalian ceramide biosynthesis.
(B–C) Ceramide synthase activities of brain microsomes from 12- to 13-day-old wild type (+/+, open bars; n=5) and fln/fln mice (filled bars; n=6). CerS
activities for C18 fatty acyl-CoA (B) and C16 fatty acyl-CoA (C) are shown as mean 6 SD. (D) In vitro C18 ceramide synthase activities of wild type and
mutant CerS1 proteins. Full-length wild type CerS1 (CerS1
wt), or CerS1
H269trunc (Lass1
fln) or CerS1
A266D (Lass1
to) were expressed in COS7 cells. Values
are mean 6 SD from three independent experiments. No significant difference of C18 ceramide synthase activity was observed between
CerS1
H269trunc and CerS1
A266D. **: p#0.01.
doi:10.1371/journal.pgen.1002063.g003
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chain is formed by fatty acyl chain desaturation after ceramide
biosynthesis (Figure 4C). Our results also confirm that C18
ceramide species are the dominant ceramide species in the mouse
brain. Ceramide is the basic building block of complex
sphingolipids, such as sphingomyelin and glycosphingolipids. In
agreement with the reduced levels of C18 ceramide species, the
amount of complex sphingolipids with C18 fatty-acyl groups was
also reduced in the fln/fln brain (Figure S5A and data not shown).
Contrary to the reduction of C18 sphingolipids observed in the
fln mutant brain, the amounts of other long-chain sphingolipids,
i.e. sphingolipids with fatty acyl chain length moiety C14 and C16,
were increased significantly, suggesting a compensatory mecha-
nism (Figure 4D, Figure S5 and data not shown). This
compensation was not likely due to an upregulation of CerS5 or
CerS6 that utilize C14 and C16 fatty acyl-CoA for ceramide
biosynthesis, given that we did not observe an increased ceramide
synthase activity with C16 fatty acid CoA in fln/fln brain
microsomes (Figure 3C). Rather, increased C14 and C16
sphingolipid levels were most likely the result of excessive substrate
availability for CerS5 and CerS6. The excessive substrate
availability for CerS5 may also underlie the similar levels of C18
dihydroceramide observed in wild type and fln/fln brains (Figure
S5C).
Sphingolipids undergo constant synthesis and degradation.
Ceramide can be generated by degradation of complex sphingo-
lipids, and be degraded further by ceramidases to release the
sphingoid base, sphingosine. Sphingosine, in turn, can be recycled
and used as the sphingoid substrate in the salvage pathway of
ceramide biosynthesis, which is also catalyzed by CerSs
(Figure 3A). Thus, loss of CerS1 function could result in
accumulation of sphingosine, and dhS, the sphingoid substrate
of de novo ceramide biosynthesis. Indeed, LC-MS analyses of fln/fln
brains revealed a 2–4 fold increase in sphingosine and a greater
than 10 fold increase in dhS (Figure 4E–4F). The phosphorylated
metabolites of sphingosine and dhS, sphingosine-1-phosphate
(S1P) and dhS-1-phosphate (dhS1P) were also significantly
increased in mutant brains (Figure 4G–4H). However, the
accumulation of dhS and dhS1P was much more pronounced
than that of sphingosine and S1P, suggesting that the de novo
ceramide biosynthesis pathway is the dominant pathway for
ceramide biosynthesis in the brain.
Figure 4. Alterations of sphingolipid homeostasis in fln mutant brains. Brain sphingolipid levels for selected sphingolipid species in 12- to
13-day-old wild type (+/+, open bars; n=6) and fln/fln mice (filled bars; n=5) were measured by mass spectrometry and normalized to protein
concentration. Total ceramide (A), and C18:0 (B), C18:1 (C), and C16:0 (D) ceramide species are shown. Sphingosine (E), dihydrosphingosine (F),
sphingosine-1-phosphate (G), dihydrosphingosine-1-phosphate (H) levels are also shown. All values are mean 6 SD. **: p#0.01.
doi:10.1371/journal.pgen.1002063.g004
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In normal aging brains and under some pathological conditions,
undigested storage materials may accumulate in neurons to form
autofluorecent deposits, termed lipofuscin. Based on the ultra-
structure of lipofuscin, it has been suggested that lipofuscin
production is a result of impaired autophagy of organelles,
especially mitochondria [27]. Consistent with this hypothesis,
mutations of several lysosomal proteins have been linked to the
neuronal ceroid lipofuscinoses (CLNs), a group of infantile- to
juvenile-onset neurodegenerative diseases that are characterized
by abnormal lipofuscin accumulation [28]. However, the recent
identification of two CLN proteins, CLN6 and CLN8, as polytopic
membrane proteins on the endoplasmic reticulum suggests that
non-lysosomal mechanisms may underlie lipofuscin accumulation
in these diseases [29–31]. Although CLN8 does not show
detectable ceramide synthase activity, ceramide profile changes
have been observed in the brains of CLN8 patients [12]. In
addition, overexpression of CLN8 or CerSs suppressed the growth
phenotype of fibroblasts from patients with CLN9, the causal gene
of which has yet to be identified [32]. These results indicate that
defects in ceramide homeostasis may contribute to accumulation
of lipofuscin.
To directly test whether a deficiency of ceramide biosynthesis
can induce lipofuscin accumulation, we examined adult fln and to
mutant brains. Although autofluorescent deposits were observed
sporadically in neurons of four-month-old wild type mice, deposits
were widespread in many brain regions in mutant mice, with the
highest abundance in deep cerebellar nuclei, pons, medulla,
anterior olfactory nuclei, layer IV to layer VI of the cerebral
cortex, and the CA3 region of the hippocampus (data not shown).
A similar pattern of deposits was observed in sections of mutant
brains that were stained with Luxol fast blue, a compound that
stains myelin and lipofuscin (Figure 5A–5B). To ascertain that
these observed deposits are indeed lipofuscin, we examined their
fine structure. Electron microscopy revealed the presence of many
vacuoles and electron dense structures in the cytoplasm of mutant
neurons (Figure 5C). Higher magnification revealed membranes
and vacuoles within these dense structures, as typically seen in
neuronal lipofuscin (Figure 5D).
Lipofuscin often contains both lipids and ubiquitylated proteins
[1]. To test whether ubiquitylated proteins also accumulate in the
lipofuscin in CerS1 mutant brains, we performed immunohisto-
chemistry using an antibody against ubiquitin. Indeed, ubiquitin-
positive deposits were observed in the same types of neurons
harboring lipofuscin, including cerebral cortical neurons, hippo-
campal CA3 neurons, and neurons in deep cerebellar nuclei, pons,
medulla and anterior olfactory nuclei (Figure 5E–5H, and data not
shown). Although the autofluorescent deposits are visible across a
wide spectrum of light, the intensity of their fluorescence is lower
than that of the fluorescent molecule-conjugated secondary
antibodies used for ubiquitin immunofluorescence, allowing
simultaneous assessment of lipofuscin and ubiquitin-positive
puncta. We found that ubiquitylated proteins and autofluorescent
deposits were largely colocalized or closely associated (Figure 5I–
5N). While lipofuscin accumulated in many neurons in the mutant
brain, we did not observe overt death of neurons other than
Purkinje cells, although we cannot rule out more subtle changes in
the survival of mutant neurons. However, as evidenced by the
hyperactivity of CerS1 mutant mice, it is likely that the function of
additional neurons is impaired in these mice.
Although lipofuscin deposition was much more pronounced in
brains of older mutant mice, we also observed weak autofluor-
escent deposits containing ubiquitin-positive puncta in the soma
and swollen dendrites of a small number of Purkinje cells in 3-week
old mutant, but not wild type, mice (Figure 5O–5Q and data not
shown). This result suggests that CerS1-deficiency also causes
accumulation of lipofuscin-like structures in at least some Purkinje
cells.
Discussion
Alterations of sphingolipids have been observed in many
neurodegenerative disorders. However, the contribution of these
changes to disease pathogenesis is not clear [5]. We have
uncovered two spontaneous mutants with progressive degenera-
tion of cerebellar Purkinje neurons and widespread lipofuscin
accumulation. By positional cloning, we identified the mutations as
alleles of the Lass1 gene, which encodes ceramide synthase 1
(CerS1), one of the six ceramide synthases in mammals. Our data
demonstrate that deficiency of CerS1/LASS1 leads to dramatic
alterations in the levels of sphingolipids in the brain, degeneration
of cerebellar Purkinje neurons, and widespread lipofuscin
accumulation.
CerS1 is specifically expressed in neurons in the brain and has
been shown to produce C18:0 ceramide species in vitro or in
cultured cells [18,19,23–25]. In the brain of Lass1 mutant mice,
C18 sphingolipid species were significantly reduced, confirming the
role of CerS1 in C18 ceramide biosynthesis in vivo. Loss of CerS1
also led to a decrease in total ceramide, in agreement with C18
ceramide as a major ceramide in the adult brain [17]. However
these sphingolipid decreases were accompanied by an increase in
the steady state levels of C14 and C16 sphingolipid species. In
addition, sphingoid bases and their phosphorylated metabolites
were drastically increased in the mutant brain.
In contrast to previous reports suggesting that ceramide is
proapoptotic in vitro and can mediate both stress-induced intrinsic
and death receptor-mediated extrinsic apoptosis [8,33], our data
suggest that reduction of ceramide or complex sphingolipids results
in progressive neuron death, particularly Purkinje cell loss.
Intracerebroventricular administration of global ceramide inhib-
itors has been reported to cause acute neurodegeneration [34].
Contrary to in vitro data, this finding, together with our results,
demonstrate that decreases in ceramide synthesis can induce
neuron death in vivo. Sphingolipid homeostasis is critically
balanced in the cell under normal conditions, and thus either
increases or decreases of ceramide could be detrimental to the cell.
Alternatively, ceramide species with different fatty acyl chains may
play distinct physiological roles. For example, loss of one of the two
worm ceramide synthases, which produce different ceramide
species, resulted in opposite outcomes in C. elegans under hypoxic
conditions [35]. Perhaps C18 ceramide, or some of its derived
sphingolipids such as C18-sphingomyelin or C18-cerebrosides, act
in a prosurvival fashion in neurons, whereas an increase in other
ceramide species, such as C16 ceramide, may be apoptotic [35].
Lastly, Purkinje neuron loss may be due to an increase in the
sphingoid bases that normally serve as substrates for CerS1.
Sphingoid bases, particularly their phosphorylated metabolites, are
potent signaling molecules and have been proposed to regulate
many signal transduction pathways [7]. Thus, elevation of these
molecules, particularly dhS and dhS1P, which are increased over
ten fold in the CerS1-deficient brain, may impair normal functions
of sphingolipid signaling, leading to Purkinje cell death.
Consistent with previous reports demonstrating that sphingo-
lipid biosynthesis is crucial for dendritic development in cultured
Purkinje or hippocampal neurons [36,37], we observed shortened
dendritic arbors and decreased density of calbindin immunostain-
ing in the molecular layer in CerS1-deficient cerebella suggesting
that dendritic development of mutant Purkinje cells was abnormal.
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PLoS Genetics | www.plosgenetics.org 7 May 2011 | Volume 7 | Issue 5 | e1002063Figure 5. Lipofuscin and ubquitylated protein accumulation in CerS1-deficient neurons. (A–B) Sections of cerebella from four-month-old
wild type (+/+, A) and fln/fln (B) mice were stained with Luxol Fast Blue. Images are converted to gray-scale for clear visualization of punctate staining.
Images of the hippocampal CA3 region are shown. (C–D) Electron micrographs showing electron-dense deposits in fln/fln neurons at five months of
age. An overview of a hippocampal neuron (C) showing vacuoles (arrowheads) and electron-dense deposits (arrows), and a lipofuscin structure from
a cortical neuron (D) showing internal membrane structures (arrows) and vacuoles (arrowheads). (E–H) Ubiquitin immunohistochemistry of the
hippocampal CA3 region from 4-month-old wild type (+/+, E, F) and fln/fln (G, H) mice. Details are shown in higher magnification (F, H). Conspicuous
ubiquitylated accumulations in an fln/fln neuron are marked with arrows (H). (I–N) Ubiquitylated proteins (Ub; I, L) and autofluorescent lipofuscin
(lipo; J, M) in a hippocampal neuron (I–K) and a cortical neuron (L–N) of a four-month-old fln/fln mouse. Merged images (K, N) show the relative
locations of the ubiquitin immunofluorescent stain and autofluorescence. (O–Q) Ubiquitin-positive inclusions in Purkinje cells of three-week old fln/fln
mice. Sections were incubated with an antibody against ubiquitin (O) and calbindin D-28 (P). Merged images are shown (Q), with Hoescht dye
counterstaining. Scale bars: 20 mm (A–B); 2 mm (C); 100 nm (D); 50 mm (E, G); 20 mm (F, H, I–N); 25 mm (O–Q).
doi:10.1371/journal.pgen.1002063.g005
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may involve sphingolipid-rich lipid rafts, which are implicated in
activity-dependent dendritic development and maintenance of
dendritic spines in in vitro experiments [38,39]. Dendritic
dysfunction or morphological anomalies are often associated with
neurodegeneration [40]. While we cannot rule out a secondary
cause for abnormalities in Purkinje cell dendrites in CerS1 mutant
mice, it is possible that defects in dendritic development also
contribute to death of these neurons.
In addition to Purkinje cell death, our data clearly demonstrate
that deficiency of ceramide biosynthesis can cause the accumula-
tion of lipofuscin, which is often observed in aging brains and in
some neurodegenerative diseases. Lipofuscin is known to contain
both lipids and proteins that may originate from membrane bound
organelles such as mitochondria [1]. Accumulation of lipofuscin
has been linked to reduced lysosomal hydrolytic capacity, based on
observations of lipofuscin deposition in mutants with deficiencies
in lysosomal proteins [1,28]. Both increases and decreases in
ceramide have been shown to induce autophagy, suggesting that
the balance of sphingolipid homeostasis is important for autophagy
and/or lysosomal functions [41,42]. Alternatively, conditions that
increase the load on lysosomes beyond their capacity may also
underlie lipofuscin formation. Given the importance of sphingo-
lipids in protein targeting and as components of membranes,
reduced sphingolipid levels may increase the demand on, and/or
decrease the capacity of lysosomal function by affecting both
lysosomal and non-lysosomal membrane dynamics, and targeting
of membrane proteins. Increased load of defective membrane
organelles and mislocalized membrane proteins could exceed
lysosomal hydrolytic capacity of neurons, resulting in lipofuscin
formation.
Previous reports suggest ceramide might also be important
during aging [43]. One of the yeast genes encoding ceramide
synthases, LAG1 (longevity assurance gene 1), was identified in a
screen for genes whose expression changed over yeast replicative
cycles [44]. Deletion of LAG1 was associated with an increase of
replicative life span in yeast. However, a LASS1 variant exhibiting
increased expression, when combined with specific HRAS1 and
APOE haplotypes, was suggested to contribute to healthy aging
and survival in a human population [45]. This finding suggests
that appropriately increased ceramide levels might be beneficial to
some cells in aging animals. Inversely, given the specificity of
Purkinje cell loss observed in CerS1-deficient mice, decreased
ceramide levels appear more detrimental to neurons, and
accelerate aging phenotypes, including lipofuscin accumulation.
Thus our results demonstrate that in addition to neurodegener-
ation, alteration of ceramide levels can accelerate some aspects of
aging. More research is needed to elucidate the role of ceramide
and other sphingolipids in aging and neurodegeneration.
Materials and Methods
Ethics statement
All experiments with mice have been approved by The Jackson
Laboratory Animal Care and Use Committee according to
relevant national and international guidelines.
DNA oligos and genotyping assays
Oligos used for plasmid construction and genotyping are listed
in Table S1. Genotyping assays are described in detail in Text S1.
Mouse strains and plasmids
The fln and to mutations were maintained on a NOD/SzJ
background and a FVB/N background, respectively. Bacterial
artificial chromosome (BAC) transgenic mouse lines were
generated by injection of purified BAC DNA into C57BL/6J
pronuclei and maintained on the same background. To generate
Lass1 cDNA transgenic lines, Lass1 cDNA was amplified from a
mouse cDNA library plasmid pME18-FL3-LASS1 (Open Biosys-
tems) with primers LZO455 and LZO456, and inserted into
pNSE-Ex4N1 at the BamHI and SpeI sites, downstream of the
neuron-specific enolase 2 gene (Nse2) promoter. The plasmid
pNSE-Ex4N1 is a modified version of pNSE-Ex4, which was
described previously [46], with BamHI, NotI and SpeI sites on an
adapter inserted into the HindIII site of pNSE-Ex4. A SalI
fragment containing the Lass1 cDNA, the Nse2 promoter and an
SV40 polyadenylation sequence was used for pronuclear micro-
injection. For expression of full-length wild type LASS1 protein in
cultured mammalian cells, the Lass1 coding region was recovered
from the pNSE-Ex4N1-LASS1 plasmid by restriction digestion
with BamHI and EcoRI, and was inserted into pCMV-3Tag-1A
(Stratagene), in frame with a 3xFLAG epitope. For expression of
mutant LASS1 proteins, Lass1 fragments were amplified from poly
A
+ RNA isolated from fln/fln or to/to mutant brains, using primers
LZO605 and LZO606. The FLAG epitope-tagged wild type
LASS1 construct was cleaved with BsrGI to swap an internal
fragment with the fragments containing the mutations.
Genome mapping
Homozygous fln mice were crossed with BALB/cByJ mice, and
F1 heterozygotes were intercrossed to generate F2 mice. Genome
scans using polymorphic microsatellite markers were performed
on DNA from ten affected and ten unaffected F2 mice. To fine
map the mutation, 951 F2 mice were analyzed using polymorphic
microsatellite markers and single nucleotide polymorphisms
(SNPs). To further narrow the critical interval, fln/fln and
CAST/EiJ were crossed, and F1 heterozygotes were intercrossed
to generate F2 mice. 1033 F2 mice were analyzed.
Preparation of RNA and northern blot analyses
Total brain RNA preparation, poly-A
+ RNA selection and
northern blot analyses were performed as described [47]. To
generate northern blot probes, fragments of Lass1 and Gdf1 coding
sequences were amplified with oligos LZO463 and LZO426, and
oligos LZO445 and LZO446, respectively.
Histology and immunohistochemistry
Immunohistochemical studies were performed as described
[48]. Briefly, mice were intracardically perfused and brains were
postfixed before dehydration and embedding in paraffin. After
antigen retrieval in 0.01 M citrate buffer (pH 6), sections were
incubated at 4uC overnight with mouse monoclonal antibody
against calbindin D-28 (Sigma-Aldrich, 1:1000) or rabbit poly-
clonal antibody against ubiquitin (DAKO, 1:200) in phosphate-
buffered saline with 0.03% Triton and 5% normal donkey serum.
Colorimetric Calbindin D-28 immunohistochemistry was per-
formed as described [49]. Fluorescent detection was performed
with Alexa Fluor-conjugated secondary antibodies (Invitrogen,
1:200). Autofluorescence was quenched by incubation with 0.01%
Sudan Black in 70% ethanol, and some sections were counter-
stained with Hoescht 33258. To detect autofluorescent deposits,
deparaffinated sections were mounted with Fluoromount-G
(Southern Biotech) without incubation with Sudan Black.
For electron microscopy, mice were intracardically perfused
with a mixture of 1.2% paraformaldehyde and 0.8% glutaralde-
hyde, and brains were postfixed and processed for transmission
electron micrography using standard procedures [50].
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COS7 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (Invitrogen) supplemented with 10% Fetal Bovine Serum
(Hyclone). Transfections were performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol.
Medium was replaced with fresh medium 12 hours after the
transfection, and cells were harvested 48 hours after transfection.
Microsomal preparation and in vitro ceramide synthase
assays
For microsomal preparation from mouse brains, the tissue was
homogenized in 20 mM HEPES buffer (pH 7.4, 2 mM KCL,
2 mM MgCl2, 250 mM sucrose) supplemented with protease
inhibitors (Sigma) with a Tissue Tearor homogenizer (Biospec
Products). For microsomal preparation from culture cells,
harvested cells were lysed in 20 mM HEPES buffer (see above)
with a 30-gauge syringe. Tissue homogenates or cell lysates were
subjected to centrifugation at 1,0006g for 5 min at 4uC to remove
unbroken tissue debris or intact cells and nuclei. The supernatants
were subjected to centrifugation at 10,0006g for 10 min at 4uCt o
remove mitochondria. The supernatants were ultracentrifuged at
100,0006g for 1 h at 4uC to collect microsomes, which were re-
suspended in HEPES buffer (see above), and protein concentra-
tions were measured with the Bradford method (BioRad). For in
vitro ceramide synthase assays, a 100 mL reaction mixture
containing 15 mMC 17 sphingosine (Avanti Polar Lipids) and
50 mMC 16,C 18 or C24 fatty acid CoA (Avanti Polar Lipids) in
25 mM potassium phosphate buffer (pH 7.4) was pre-warmed at
37uC for 5 min. The enzymatic reaction was initiated by adding
microsomes (15 mg) to the reaction mixture, which was incubated
at 37uC for 15 min, and the reaction was terminated by adding
2 mL extraction solvent (ethyl acetate/iso-propanol/water at 60/
30/10 v/v/v), supplemented with d13/C16 ceramide and d13/C22
ceramide as internal standards for mass spectrometry analyses.
Lipid extraction and liquid chromatography/mass
spectrometry (LC/MS) analyses of sphingolipids
Lipid extractions and LC/MS analyses were performed as
described previously [51]. Briefly, samples were fortified with internal
standards. Lipids were extracted twice with 2 ml ethyl acetate/
isopropanol/water (60/30/10 v/v) solvent system, dried under a
stream of nitrogen, re-suspended into 150 mL1m MN H 4COOH in
0.2% HCOOH in methanol, and analyzed by LC/MS. LC/MS
analyses of sphingolipids were performed on a Thermo Finnigan
TSQ 7000 triple quadrupole mass spectrometer, operating in a
MultipleReactionMonitoringpositiveionizationmode.Sphingolipid
levels in the brain homogenates were normalized to protein
concentration measured by the Bradford method.
Western blot
Protein samples were separated on SDS gels (BioRad) and
transferred to a nitrocellulose membrane (Amersham Biosciences)
using standard techniques [52]. FLAG-tagged proteins were
detected using M2 mouse monoclonal antibody against FLAG
(Sigma). Mouse monoclonal N
+/K
+-ATPase antibody (Abcam)
was used as a loading control. Primary antibodies were detected
with an appropriate secondary antibodies conjugated with
horseradish peroxidase, and detected with ECL (Amersham
Pharmacia).
Data analyses
In vitro ceramide synthase assays and mass spectrometry data
were analyzed with Sigma Plot. Paired t-tests were performed.
Supporting Information
Figure S1 Haplotypes of selected recombinants used to refine
the critical interval of the fln mutation. F2 recombinants from
NOD.CB17-Prkdc
scid/J-fln6BALB/cJ and NOD.CB17-Prkdc
scid/J-
fln6CAST/EiJ crosses are shown with the number of recombi-
nants with each haplotype indicated.
(TIF)
Figure S2 BAC rescue of the fln mutation. (A) The critical
interval of the flincher mutation. The three BAC clones used in
the BAC complementation experiments are shown. (B–C)
Calbindin-D28 immunostaining of cerebellar sections from a
seven-week-old fln/fln mouse and an age-matched fln/fln
littermate carrying the BAC RP23-349E13 transgene. Scale
bar: 1 mm (B–C).
(TIF)
Figure S3 A neuron-specific Lass1 cDNA transgene suppresses
the toppler mutation. Calbindin D-28 immunohistochemistry of
cerebellar sections from eight-week-old to/to (A) and to/to;
Tg(NSE-Lass1) (B) mice. Scale bar: 1 mm.
(TIF)
Figure S4 The fln and the to mutations are in the conserved
TLCdomain.(A)Predicted secondarystructureofthe mouse CerS1.
Transmembrane domains were predicted with the TMPred server
(http://www.ch.embnet.org/software/TMPRED_form.html) and
combined with topological data of yeast ceramide synthases [53].
The to and the fln mutations are marked with arrowheads. The TLC
domain is indicated in light green, and the LAG1 motif in the TLC
domain is shaded in darker green. (B) Alignment of CerS1 orthologs
using COBALT (http://www.ncbi.nlm.nih.gov/tools/cobalt/).
Identical or similar residues across all species are colored red or
orange, respectively. Residues conserved in vertebrates are indicated
in yellow. Transmembrane domains were marked according to the
mouse CerS1 sequence. Arrowheads denote the fln and the to
mutations.ResiduesthatareidenticalorconservedinmouseCerS1–
CerS6 are marked with filled and open circles, respectively.
Sequences used for analysis are NP_067090 (human), NP_619588
(mouse), NP_001037695 (rat), CAK11083 (Zebra fish), NP_727075
(Drosophila, fly), and NP493403 (C. elegans,w o r m ) .
(TIF)
Figure S5 Mass spectrometry data showing profound changes of
sphingolipids in the fln mutant brain. Brain sphingolipid levels in
12- to 13-day-old wild type (+/+, open bars; n=5) and fln/fln
mouse brains (filled bars; n=6) were measured by mass
spectrometry and normalized to protein concentration. (A)
Abundance of sphingomyelin with different fatty acyl chain
moieties. (B) Abundance of ceramide with different fatty acyl
chain moieties. Note that C16 and C18 ceramide species are shown
in Figure 4, and are not included here. (C) Abundance of
dihydroceramide with different fatty acyl chain moieties. All values
are mean 6 SD. *: p#0.05; **: p#0.01.
(TIF)
Table S1 Primers used to construct plasmids or used for
genotyping.
(DOC)
Text S1 Genotyping assays.
(DOC)
Video S1 Mice homozygous for the fln mutation display severe
cerebellar ataxia. A four-month old fln/fln and an age-matched
wild type (+/+) littermate are shown.
(MP4)
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